`FOR THE DISTRICT OF DELAWARE
`ALNYLAM
`PHARMACEUTICALS, INC.,
`Plaintiff,
`V.
`PFIZER, INC., PHARMACIA &
`UPJOHN CO. LLC, BIONTECH
`SE, and BIONTECH
`MANUFACTURING GMBH,
`Defendants.
`Civil Action No. 22-336-CFC
`( consolidated)
`ORDER
`Pending before me is the Motion for Summary Judgment of Invalidity under
`35 U.S.C. § 112 filed by Defendants Pfizer Inc., Pharmacia & Upjohn Co. LLC,
`BioNTech SE, and BioNTech Manufacturing GmbH. D.I. 289.
`In support of their motion, Defendants argue first that three of the thirteen
`asserted claims are invalid for improper dependency under 35 U.S.C. § 112(d)
`because I "effectively nullif[ied]" the three claims in the Revised Memorandum
`Opinion I issued on September 9, 2024 (D.1. 248). D.I. 290 at 1, 5 (alteration in
`the original). I did not, however, nullify any claims in the Revised Memorandum
`Opinion.
`Case 1:22-cv-00336-CFC Document 447 Filed 04/29/25 Page 1 of 2 PageID #: 55888
`
`
`
`
`
`
`
`Defendants next argue that all the asse1ied claims are invalid for lack of
`adequate written description because the "reasoning underlying [my] construction"
`of "head group" in the Revised Memorandum Opinion "necessarily renders th[ e]
`claims invalid under§ l 12(a) as well." D.I. 290 at 6-8. I did not, howe ver, make
`a finding of fact in the Revised Memorandum Opinion that the written description
`of the asserted patents did not "reasonably convey[] to those skilled in the art that
`the inventor had possession of the claimed subject matter as of the filing date."
`Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010).
`Accord ingly, Defendants are not "entitled to judgment as a matter of law"
`that all asserted claims are invalid. Fed. R. Civ. P. 56(a).
`NOW THEREFORE, at Wilmington on this Twenty-ninth day of Apr il in
`2025, Defendants' Motion for Summary Judgment of Invalidity under 35 U.S.C. §
`112 (D.I. 289) is DENIED.
`~GE
`2
`Case 1:22-cv-00336-CFC Document 447 Filed 04/29/25 Page 2 of 2 PageID #: 55889
`
`
`
`
`
`
`
`



